Detalhe da pesquisa
1.
Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases.
J Biol Chem
; 284(41): 28093-28103, 2009 Oct 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-19679662
2.
Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients.
Rheumatology (Oxford)
; 49(12): 2281-9, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20739362
3.
Design, synthesis, and in vitro activity of peptidomimetic inhibitors of myeloid differentiation factor 88.
J Med Chem
; 51(5): 1189-202, 2008 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-18275134
4.
Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.
J Leukoc Biol
; 82(4): 801-10, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17548806
5.
ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors.
J Med Chem
; 57(20): 8358-77, 2014 Oct 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25233084
6.
Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B.
J Biol Chem
; 280(16): 15809-14, 2005 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-15755740